S&P 500   4,549.34 (-0.39%)
DOW   36,054.43 (-0.19%)
QQQ   385.05 (-0.58%)
AAPL   192.32 (-0.57%)
MSFT   368.80 (-1.00%)
META   317.45 (-0.26%)
GOOGL   130.02 (-0.74%)
AMZN   144.52 (-1.61%)
TSLA   239.37 (+0.27%)
NVDA   455.03 (-2.28%)
NIO   7.75 (+4.31%)
BABA   71.49 (-1.23%)
AMD   116.82 (-1.32%)
T   16.94 (-1.63%)
F   10.69 (+0.85%)
MU   73.13 (-0.76%)
CGC   0.70 (+4.70%)
GE   119.81 (-0.35%)
DIS   91.50 (+0.78%)
AMC   6.79 (-3.28%)
PFE   28.79 (-1.03%)
PYPL   59.53 (+2.78%)
XOM   99.11 (-1.32%)
S&P 500   4,549.34 (-0.39%)
DOW   36,054.43 (-0.19%)
QQQ   385.05 (-0.58%)
AAPL   192.32 (-0.57%)
MSFT   368.80 (-1.00%)
META   317.45 (-0.26%)
GOOGL   130.02 (-0.74%)
AMZN   144.52 (-1.61%)
TSLA   239.37 (+0.27%)
NVDA   455.03 (-2.28%)
NIO   7.75 (+4.31%)
BABA   71.49 (-1.23%)
AMD   116.82 (-1.32%)
T   16.94 (-1.63%)
F   10.69 (+0.85%)
MU   73.13 (-0.76%)
CGC   0.70 (+4.70%)
GE   119.81 (-0.35%)
DIS   91.50 (+0.78%)
AMC   6.79 (-3.28%)
PFE   28.79 (-1.03%)
PYPL   59.53 (+2.78%)
XOM   99.11 (-1.32%)
S&P 500   4,549.34 (-0.39%)
DOW   36,054.43 (-0.19%)
QQQ   385.05 (-0.58%)
AAPL   192.32 (-0.57%)
MSFT   368.80 (-1.00%)
META   317.45 (-0.26%)
GOOGL   130.02 (-0.74%)
AMZN   144.52 (-1.61%)
TSLA   239.37 (+0.27%)
NVDA   455.03 (-2.28%)
NIO   7.75 (+4.31%)
BABA   71.49 (-1.23%)
AMD   116.82 (-1.32%)
T   16.94 (-1.63%)
F   10.69 (+0.85%)
MU   73.13 (-0.76%)
CGC   0.70 (+4.70%)
GE   119.81 (-0.35%)
DIS   91.50 (+0.78%)
AMC   6.79 (-3.28%)
PFE   28.79 (-1.03%)
PYPL   59.53 (+2.78%)
XOM   99.11 (-1.32%)
S&P 500   4,549.34 (-0.39%)
DOW   36,054.43 (-0.19%)
QQQ   385.05 (-0.58%)
AAPL   192.32 (-0.57%)
MSFT   368.80 (-1.00%)
META   317.45 (-0.26%)
GOOGL   130.02 (-0.74%)
AMZN   144.52 (-1.61%)
TSLA   239.37 (+0.27%)
NVDA   455.03 (-2.28%)
NIO   7.75 (+4.31%)
BABA   71.49 (-1.23%)
AMD   116.82 (-1.32%)
T   16.94 (-1.63%)
F   10.69 (+0.85%)
MU   73.13 (-0.76%)
CGC   0.70 (+4.70%)
GE   119.81 (-0.35%)
DIS   91.50 (+0.78%)
AMC   6.79 (-3.28%)
PFE   28.79 (-1.03%)
PYPL   59.53 (+2.78%)
XOM   99.11 (-1.32%)

ESSA Pharma Stock Price, News & Analysis (NASDAQ:EPIX)

$5.05
-0.25 (-4.72%)
(As of 04:00 PM ET)
Compare
Today's Range
$4.91
$5.36
50-Day Range
$2.74
$6.00
52-Week Range
$2.29
$6.40
Volume
58,942 shs
Average Volume
128,427 shs
Market Capitalization
$222.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.00

ESSA Pharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
236.0% Upside
$17.00 Price Target
Short Interest
Bearish
6.91% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$454,274 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.69) to ($1.06) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.80 out of 5 stars

Medical Sector

709th out of 953 stocks

Pharmaceutical Preparations Industry

309th out of 405 stocks


EPIX stock logo

About ESSA Pharma Stock (NASDAQ:EPIX)

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. The company develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. It has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

EPIX Stock Price History

EPIX Stock News Headlines

Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
ESSA Pharma: Q2 Earnings Insights
ESSA Pharma Inc. (EPIX)
See More Headlines
Receive EPIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ESSA Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/18/2021
Today
12/06/2023
Next Earnings (Estimated)
12/12/2023
Fiscal Year End
9/30/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EPIX
Employees
50
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$17.00
High Stock Price Target
$17.00
Low Stock Price Target
$17.00
Potential Upside/Downside
+236.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-35,100,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.79 per share

Miscellaneous

Free Float
38,809,000
Market Cap
$223.15 million
Optionable
Not Optionable
Beta
1.97
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Dr. David Ross Parkinson M.D. (Age 73)
    President, CEO & Director
    Comp: $798k
  • Mr. David S. Wood C.M.A. (Age 66)
    CPA, CMA, CPA, M.B.A., MBA, Chief Financial Officer
    Comp: $573.32k
  • Mr. Peter A. Virsik M.B.A. (Age 52)
    M.S., Executive VP & COO
    Comp: $625.36k
  • Dr. Alessandra Cesano M.D. (Age 62)
    Ph.D., Chief Medical Officer & Executive VP
    Comp: $598.03k
  • Chandtip Chandhasin
    Executive
  • Erica Osbourne
    Executive
  • Erin Rudsinski
    Executive
  • Loleta Harris
    Executive
  • Neil Thapar
    Executive
  • Nkengyal Barber
    Executive














EPIX Stock Analysis - Frequently Asked Questions

Should I buy or sell ESSA Pharma stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ESSA Pharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" EPIX shares.
View EPIX analyst ratings
or view top-rated stocks.

What is ESSA Pharma's stock price target for 2024?

1 equities research analysts have issued 12 month price targets for ESSA Pharma's shares. Their EPIX share price targets range from $17.00 to $17.00. On average, they predict the company's stock price to reach $17.00 in the next year. This suggests a possible upside of 236.0% from the stock's current price.
View analysts price targets for EPIX
or view top-rated stocks among Wall Street analysts.

How have EPIX shares performed in 2023?

ESSA Pharma's stock was trading at $2.52 at the start of the year. Since then, EPIX shares have increased by 100.8% and is now trading at $5.06.
View the best growth stocks for 2023 here
.

When is ESSA Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, December 12th 2023.
View our EPIX earnings forecast
.

How were ESSA Pharma's earnings last quarter?

ESSA Pharma Inc. (NASDAQ:EPIX) announced its earnings results on Thursday, November, 18th. The company reported ($0.20) earnings per share for the quarter, beating analysts' consensus estimates of ($0.23) by $0.03.

What other stocks do shareholders of ESSA Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ESSA Pharma investors own include RedHill Biopharma (RDHL), Aurinia Pharmaceuticals (AUPH), Lipocine (LPCN), Trevena (TRVN), Allena Pharmaceuticals (ALNA), Agile Therapeutics (AGRX), Biopharmx (BPMX), Corbus Pharmaceuticals (CRBP) and Heat Biologics (HTBX).

Who are ESSA Pharma's major shareholders?

ESSA Pharma's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Rock Springs Capital Management LP (1.54%), Rhenman & Partners Asset Management AB (0.53%), Group One Trading L.P. (0.09%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David Ross Parkinson, Franklin M Berger and Growth N V Biotech.
View institutional ownership trends
.

How do I buy shares of ESSA Pharma?

Shares of EPIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:EPIX) was last updated on 12/6/2023 by MarketBeat.com Staff

My Account -